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Bartonellae are bacterial pathogens for a wide variety of mammals. In humans, bartonellosis can result in
angioproliferative lesions that are potentially life threatening to the patient, including bacillary angiomatosis,
bacillary peliosis, and verruga peruana. The results of this study show that Bartonella bacilliformis, the agent
of Oroya fever and verruga peruana, produces a proteinaceous mitogen for human vascular endothelial cells
(HUVECs) that acts in a dose-dependent fashion in vitro with maximal activity at >72 h of exposure and
results in a 6- to 20-fold increase in cell numbers relative to controls. The mitogen increases bromodeoxyuri-
dine (BrdU) incorporation into HUVECs by almost twofold relative to controls. The mitogen is sensitive to heat
and trypsin but is not affected by the lipopolysaccharide inhibitor polymyxin B. The mitogen does not affect
caspase 3 activity in HUVECs undergoing serum starvation-induced apoptosis. The Bartonella mitogen was
found in bacterial culture supernatants, the soluble cell lysate fraction, and, to a lesser degree, in insoluble cell
fractions of the bacterium. In contrast, soluble cell lysate fractions from closely related B. henselae, although
possessing significant mitogenicity for HUVECs, resulted in only about a twofold increase in cell numbers.
Biochemical and immunological analyses identified GroEL as a participant in the observed HUVEC mitoge-
nicity. A B. bacilliformis strain containing the intact groES-groEL operon on a multicopy plasmid was generated
and used to demonstrate a correlation between HUVEC mitogenicity and GroEL levels in the lysate (r2  0.85).
Antiserum to GroEL significantly inhibited mitogenicity of the lysate. Data also show that GroEL is located in
the soluble and insoluble fractions (including inner and outer membranes) of the cell and is actively secreted
by B. bacilliformis.
Human infection by Bartonella species can result in angio-
proliferative lesions that stem from bacterium-induced hyper-
proliferation of the vasculature (1, 37). This pathology is
unique among pathogenic bacteria and resembles Kaposi’s sar-
coma. The earliest study investigating this phenomenon iden-
tified a factor with a size of 12 kDa in the soluble fraction of
a Bartonella bacilliformis cell homogenate that was specifically
mitogenic for vascular endothelial cells (17). Human umbilical
vein endothelial cells (HUVECs) treated with the factor
showed proliferation rates approximately threefold greater
than those in controls. The absence of cytotoxic effects coupled
with heat sensitivity led the authors to conclude that the factor
was not lipopolysaccharide (LPS). This study also demon-
strated that the factor was angiogenic in a rat model. A sub-
sequent study by this group showed that live B. bacilliformis
could stimulate proliferation of HUVECs in cocultures (16).
A study with Bartonella henselae showed enhanced prolifer-
ation and migration of HUVECs in coculture and identified a
trypsin-sensitive proliferative factor detectable in the insoluble
(cell wall) fraction of the bacterium (10). Further work with B.
henselae demonstrated that the proliferative factor was se-
creted into the culture medium and, like the B. bacilliformis
factor, was specific to endothelial cells (27). More recently,
Kirby and Nekorchuk (23) showed that inhibition of apoptosis,
and not mitogenicity, is the predominant means by which sev-
eral B. henselae strains apparently increase the number of
HUVECs in coculture. Their data also show that the antiapo-
ptotic factor is released into the bacterial culture medium and,
as previously demonstrated, is specific for endothelial cells.
Two additional studies have shown that B. henselae infection
induces expression of potentially angiogenic cytokines and
growth factors in vitro that may act in a paracrine and/or
autocrine fashion to stimulate growth of endothelial cells.
Kempf et al. showed that piliated B. henselae cells induce
synthesis of vascular endothelial growth factor (VEGF) by
EA.hy 926 or HeLa cells, but not HUVECs, in cocultures (22).
HUVEC cultures supplemented with conditioned medium
from EA.hy 926-B. henselae cocultures showed proliferation
rates 30- to 70-fold greater than those in controls. Kempf et al.
also showed that EA.hy 926-B. henselae cocultures induced
synthesis of interleukin-8 (IL-8), a second angiogenic factor
(39). Finally, this study demonstrated that B. henselae growth
correlated with host cell growth rates, suggesting that para-
crine stimulation might provide additional host cells for colo-
nization. More recently, Resto-Ruiz et al. (29) demonstrated
that VEGF and IL-1 could be detected within 6 to 12 h in
medium from THP-1 macrophage cells cocultured with B.
henselae. Conditioned medium from these cocultures was mi-
togenic for human microvascular endothelial cells (HMEC-1).
In addition, HMEC-1 cells, but not THP-1 cells, were stimu-
lated to produce IL-8 within 6 h of infection. Taken together,
these two studies suggest that proliferation of endothelial cells
during Bartonella infection may be enhanced by paracrine stim-
ulation with VEGF, IL-1, and IL-8 and a possible IL-8 auto-
crine loop.
* Corresponding author. Mailing address: Division of Biological Sci-
ences, The University of Montana, Missoula, MT 59812-4824. Phone:
(406) 243-5972. Fax: (406) 243-4184. E-mail: mike.minnick@mso.umt-
.edu.
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In this study, we analyzed a B. bacilliformis proliferative
factor to help elucidate its molecular structure and function.
Our results suggest that B. bacilliformis produces a protein-
aceous, soluble factor that is mitogenic for HUVECs and does
not affect apoptosis during a 6-h serum starvation period. Mi-
togenicity directly correlates with dosage and occurs maximally
at 72 h, resulting in cell numbers 6- to 20-fold greater than
those in controls. Furthermore, our data indicate that B.
henselae lysates are much less mitogenic than B. bacilliformis
lysates, suggesting these related pathogens use different means
of enhancing host cell proliferation. Our biochemical and im-
munological analyses show that GroEL is involved in the ob-
served HUVEC mitogenicity.
MATERIALS AND METHODS
Bacterial strains, cell lines, and cell culture. B. bacilliformis KC583 (ATCC
35685) or JB584 (5) cells were grown for 4 days at 30°C in 100% relative humidity
on heart infusion agar blood plates (HIAB; heart infusion agar [Difco, Detroit,
Mich.] containing 4% sheep erythrocytes and 2% sheep serum). B. henselae
strain Houston R1302 (ATCC 49793) was grown for 3 days at 37°C, 5% CO2, and
100% relative humidity on HIAB. Escherichia coli strains were grown overnight
in Luria-Bertani (LB) broth or plates with appropriate antibiotics as needed.
HUVEC cultures were purchased and grown at 37°C in 5% CO2 and 100%
relative humidity in EGM (Clonetics, Walkersville, Md.). HUVECs were only
used at passages 2 through 6 to minimize variation between experiments.
Bacterial cell fractionation. B. bacilliformis and B. henselae cell lysates were
prepared by harvesting several HIAB plates of bacteria into ice-cold phosphate-
buffered saline (PBS; pH 7.4) and disrupting the cells for 3 min by using 0.1-
mm-diameter glass beads and a Mini-Beadbeater 8 (BioSpec, Bartlesville,
Okla.). Particulates were removed from the mixture by centrifugation at 16,000
 g for 5 min and/or ultracentrifugation at 100,000  g for 60 min. The resulting
lysate was tested for mitogenicity and served as starting material for chromato-
graphic fractionations. Inner and outer membranes were isolated from total
membrane preparations of B. bacilliformis using a sucrose step-gradient ultra-
centrifugation protocol as previously described (8, 9).
B. bacilliformis was exposed to a temperature upshift to determine if mitoge-
nicity of the lysate could be enhanced. Thirty HIAB plates containing B. bacil-
liformis were divided into two groups, from which half were maintained at 30°C
and the others upshifted to 37°C. Following a 6-h incubation, the plates were
removed and harvested into PBS (pH 7.4). The resulting cells were washed twice
by centrifugation for 5 min at 4,500  g and resuspension in PBS. A lysate was
prepared from each group as described above.
Culture supernatants were prepared by harvesting Bartonella from HIAB
plates (or E. coli DH5 from LB plates), into recovery broth (RB): heart infusion
broth containing 5% (wt/vol) bovine serum albumin and 5% (vol/vol) sheep
erythrocyte lysate (6). The suspension was centrifuged for 10 min at 4,500  g,
the supernatant was discarded, and the resulting pellet was gently resuspended in
RB to an optical density at 600 nm (OD600) of 1.0. The Bartonella and E. coli
suspensions were then incubated for 16 h at 30 and 37°C, respectively. Following
incubation, the mixtures were centrifuged for 10 min at 4,500  g, and the
resulting supernatants were collected, filter sterilized (0.22-m-pore-size filter),
and immediately tested for HUVEC mitogenicity.
Secreted proteins of B. bacilliformis were identified by harvesting B. bacillifor-
mis cultures grown at 25°C into 10 ml of RB at 25°C to an OD600 of 0.6. The
suspension was centrifuged for 10 min at 4,500  g, and the resulting pellet was
FIG. 1. HUVEC numbers as a function of increasing doses of B.
bacilliformis lysate in the M199-FCS (20% vol/vol) culture medium.
(A) Linear (r2  0.99) calibration curve showing acid phosphatase
activity as a function of viable, adherent HUVEC numbers determined
by a hemocytometer. All phosphatase values reported in this study fall
within the range of this curve. Dose-response curves were determined
by an acid phosphatase assay (B) or a BrdU proliferation assay kit
(Oncogene) (C). Data were obtained at 96 h and represent the average
of three experiments 	 standard error. Raw, raw lysate; heated, lysate
pretreated at 100°C for 7 min.
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gently resuspended in 10 ml of RB and centrifuged again. The final pellet was
resuspended in 1 ml of RB and equilibrated for 10 min at 25 or 37°C. Three
hundred microcuries of Express [35S]methionine-cysteine mix (Perkin-Elmer,
Boston, Mass.) was then added, and the mixture was incubated for an additional
30 min with gentle mixing every 10 min. Cells were subsequently removed by
centrifugation at 6,000  g for 5 min, and the supernatants were analyzed by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), fol-
lowed by immunoblotting and autoradiography of the blot.
Endothelial cell growth, proliferation, and apoptosis assays. For growth and
proliferation experiments, EGM (Clonetics) was replaced with M199 medium
(BioWhittaker, Walkersville, Md.) supplemented with penicillin (100 U/ml),
streptomycin (0.1 mg/ml), amphotericin B (0.25 g/ml) (Sigma Chemical, St.
Louis, Mo.), and 20% fetal bovine serum (HyClone Laboratories, Logan, Utah).
HUVECs were harvested and used to seed 96-well plates with 1,000 cells/well.
Each well was brought to a total volume of 100 l with Bartonella lysate or the
fraction to be tested, antiserum, or appropriate controls (e.g., PBS, heated
fraction, preimmune serum) plus growth medium. Adherent cell numbers were
indirectly determined at 96 h postinoculation by an acid phosphatase assay (11).
Strict measurement of cytosolic acid phosphatase was ensured by thoroughly
rinsing HUVEC cultures with PBS to remove nonadherent cells and any acid
phosphatase released from dead or dying cells. The assay was calibrated with a
linear standard curve (Fig. 1A; r2  0.99) showing acid phosphatase activity as a
function of viable, adherent HUVEC numbers (0 to 36,000 cells by hemocytom-
eter) and encompassed all OD405 values reported in this study (0 to 1.4 OD405
units). A proliferation assay was also performed on 96-h cultures with a bro-
modeoxyuridine (BrdU) enzyme-linked immunosorbent assay (ELISA) kit per
the manufacturer’s instructions (Oncogene, La Jolla, Calif.). Mitogenicity of
Bartonella lysate on HUVECs was also demonstrated by BrdU incorporation
over a 48-h period by ELISA exactly as previously described for B. henselae-
HUVEC cocultures (23).
Heat, tryspinization, and polymyxin B were examined for their potential in-
hibitory effect on lysate mitogenicity. Heated lysates were prepared by incubating
for 7 min at 100°C. Trypsinized lysates were prepared by incubating for 40 min
at 37°C with trypsin (0 to 1.7 mg/ml). Trypsin was then inactivated with fetal calf
serum (FCS; 25% final concentration) prior to addition to HUVEC cultures.
Polymyxin B (1,000 U/ml) was mixed with lysate, incubated for 1 h at 37°C, and
then added to HUVECs to test for lipopolysaccharide (LPS) inhibition. Control
cultures treated with polymyxin B or lysate alone were done in parallel.
A caspase 3 assay kit (Promega, Madison, Wisc.) was used to determine if B.
bacilliformis lysate could inhibit apoptosis in HUVECs. HUVECs were grown to
90% confluency in EGM (Clonetics). Apoptosis was induced by a 6-h serum
starvation as previously described (23), in the presence of 50 M Z-VAD-FMK
(a cell-permeable pan-caspase inhibitor) or B. bacilliformis lysate (10 g of
protein/ml). Following incubation, treated HUVECs were harvested, and cell
extracts were prepared and analyzed by a CaspACE colorimetric assay, as in-
structed by the manufacturer (Promega).
Protein assay, SDS-PAGE, and immunoblot analysis. Protein concentrations
of samples were determined with a bicinchoninic protein assay kit and a bovine
serum albumin standard (Pierce, Rockford, Ill.). SDS-PAGE was done by stan-
dard methods (3). Briefly, protein samples were solubilized in an equal volume
of Laemmli sample buffer (LSB), boiled for 10 min, and then separated (20 g
of protein/lane) on 12.5% (wt/vol) acrylamide SDS-PAGE gels. Resulting gels
were fixed and stained with Coomassie brilliant blue or AgCl by standard pro-
tocols (3, 38). Immunoblots were prepared by transferring unfixed or unstained
gels to supported nitrocellulose (0.45-m pore size; Osmonics, Minnetonka,
Minn.) by the general methods of Towbin et al. (35). Blots were probed with a
1:1,000 dilution of rabbit anti-E. coli GroEL antibodies, rabbit anti-E. coli GroES
antibodies (Sigma), rabbit anti-B. bacilliformis whole-cell antiserum (32), or
rabbit anti-B. bacilliformis GroEL antiserum prepared as described below.
Horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (IgG)
(Sigma) was used at a 1:2,000 dilution to detect the primary antibody-antigen
complexes. Bands were visualized by using H2O2 and 4-chloronaphthol as pre-
viously described (32). Autoradiographs were prepared by exposing XAR-5
X-ray film (Kodak, Rochester, N.Y.) to the immunoblots overnight.
Column chromatography. A Biologic high-resolution chromatography system
(Bio-Rad, Hercules, Calif.) was used to identify and purify the mitogenic protein
from B. bacilliformis lysates. Briefly, lysates were dialyzed overnight against a
mixture of 50 mM Tris (pH 8.0), 0.5 mM EDTA, and 10% glycerol and then
loaded onto a 1-ml Econo-Pac High Q cartridge (Bio-Rad). The column was
then eluted with a 15-ml linear gradient from 0 to 0.5 M NaCl at 1 ml/min,
followed by a 5-ml gradient from 0.5 to 1 M NaCl (in 50 mM Tris [pH 8.0], 0.5
mM EDTA, 10% glycerol) at 1 ml/min. Resulting fractions (1 ml) of this and all
other chromatographic preparations were individually tested for mitogenic ac-
tivity in HUVEC cultures, and their protein profiles were analyzed by SDS-
PAGE.
Mitogenic fractions from the High Q purification were pooled and dialyzed
overnight against 10 mM sodium phosphate (pH 6.8) and 10% glycerol. The
mixture was then loaded onto a 5-ml Econo-Pac CHT-II hydroxyapatite column
(Bio-Rad). The column was subsequently eluted with a 50-ml linear gradient of
10 to 450 mM sodium phosphate (pH 6.8) in 10% glycerol, followed by a 10-ml
linear gradient of 450 to 900 mM sodium phosphate (pH 6.8) in 10% glycerol at
1 ml/min. The resulting fractions (1 ml) were dialyzed overnight against PBS (pH
7.4) and filter sterilized.
Mitogenic fractions obtained from the High Q purification were also dialyzed
against a mixture of 10 mM sodium phosphate (pH 6.8), 0.5 mM EDTA, and
10% glycerol and loaded onto a 1.3-ml UNO S1 column (Bio-Rad). This column
was eluted with a 15-ml linear gradient of 0 to 0.5 M NaCl and 0.5 to 5 mM
EDTA, followed by a 5-ml linear gradient of 0.5 to 1 M NaCl and 5 to 10 mM
EDTA (in 10 mM sodium phosphate [pH 6.8], 10% glycerol) at 1 ml/min.
Resulting fractions were dialyzed against PBS (pH 7.4) and filter sterilized.
DNA manipulation, cloning, and expression of groEL and the groES-groEL
operon. The B. bacilliformis groEL gene was cloned by a PCR-based strategy.
Briefly, PCR primers were designed from a groEL sequence (GenBank accession
no. Z15160), including BbGroEL-Fwd (ATGGCTGCTAAAGAAGTAAAAT
TTG) and BbGroEL-Rev (TTAGAAATCCATTCCGCCCATTC). PCR was
done with a GeneAmp PCR reagent kit per the manufacturer’s instructions
(Applied Biosystems, Branchburg, N.J.) together with 0.1 g of each primer per
100-l reaction mixture. Thirty cycles of 1 min at 94°C, 2 min at 55°C, and 2 min
at 72°C were done with a GeneAmp 2400 thermal cycler (Perkin-Elmer). The
resulting amplicon was purified from an ethidium bromide-stained 1% agarose
gel with a GenClean II kit per the manufacturer’s instructions (Qbiogene, Carls-
bad, Calif.). The purified groEL amplicon was cloned into pCR2.1-TOPO and
used to transform E. coli (TOP10) by using a TOPO TA cloning kit per the
manufacturer’s instructions (Invitrogen, Carlsbad, Calif.). The resulting plasmid,
pGROEL-TOPO, was purified to high concentration with a Midi-Prep kit (Qia-
gen, Valencia, Calif.).
pGROEL-TOPO was digested to completion with PstI and BamHI to yield a
1,600-bp fragment of groEL. The fragment was subsequently recloned into
compatible sites of pQE31 (Qiagen) by standard protocol (3), to generate an
N-terminal six-histidine translational fusion construct, termed pQE31-GROEL.
To induce expression of the groEL fusion, E. coli M15-(pREP4) harboring
pQE31-GROEL was grown for 1 h at 37°C with shaking (250 rpm). Isopropyl-
-D-thiogalactosidase (IPTG) was added to a final concentration of 1 mM, and
the incubation was allowed to continue for an additional 2.75 h. The bacteria
were subsequently harvested, and recombinant GroEL was batch purified from
the lysates by affinity chromatography with Ni-nitrilotriacetic acid resin per the
manufacturer’s instructions (Qiagen). The resulting recombinant GroEL was
dialyzed overnight against PBS (pH 7.4) prior to use in HUVEC cultures.
A functional groES-groEL operon of B. bacilliformis was also cloned. The
amplicon produced by the BbGroEL primers described above was used to probe
a 
 ZAP Express (Stratagene, La Jolla, Calif.) library of B. bacilliformis. Radio-
labeling of the probe and high-stringency DNA hybridizations were done as
described before (5). In vivo excision of a 
 clone was done per the manufac-
turer’s instructions, resulting in pGROESL-CMV. Automated sequence analysis
of this plasmid was done as previously described (8) with divergent primers for
the 5 and 3 ends of groEL, to verify that the operon was intact. PCR primers for
the entire operon were designed from the resulting sequence (BbGroESL Oper-
on-Fwd, TTAAATCGACGTATAAAGAAATTTG; and BbGroESL Operon-
Rev, CTTTTACAATGCAGCTCTTTCAATG). PCR with these primers was
done as described above, and the amplicon was cloned into pCR2.1-TOPO
according to the manufacturer’s instructions (Invitrogen), producing pGROESL-
TOPO. The operon was subsequently recloned by a standard method (3) into the
shuttle vector pBBR1-MCS2 (24) to produce pGRO1. The pGRO1 construct
was then electroporated into B. bacilliformis (strain JB584) as previously de-
scribed (5), to generate strain LSS100. A control strain was made by transform-
ing JB584 with pBBR1-MCS2, to form strain LSS001.
Antibodies. Recombinant GroEL was prepared as described above, solubilized
with LSB, and applied to preparative SDS-PAGE gels (12.5% acrylamide gels
without wells). Resulting gels were rinsed twice for 10 min in distilled water and
then stained with Coomassie brilliant blue (0.05% [wt/vol] in H2O). Visible
GroEL bands were excised from the gels and used to generate rabbit anti-GroEL
antiserum as previously described, at a dosage of 0.1 mg of GroEL per immu-
nization (32). Antibodies to the B. bacilliformis whole-cell and flagellin protein
were previously described and employed in this study (32). Bacteriophage-like
particles (BLPs) were prepared as described before (4) and used to generate
anti-BLP antiserum as previously detailed (32). To examine antibody-mediated
VOL. 71, 2003 BARTONELLA GroEL AND VASCULAR ENDOTHELIAL CELLS 6935
inhibition of mitogenicity, 0.6 l of lysate and 12 l of rabbit anti-B. bacilliformis
GroEL antiserum or preimmune serum as a control were incubated for 2 h at
25°C. The mixture was then brought to 900 l with M199-FCS (20%) and
aliquoted to HUVEC cultures at 100 l/well.
Statistical analysis. Statistical significance was determined with Student’s t
test. A P value of  0.05 was considered significant for all studies. Experiments
were performed a minimum of three times in triplicate. Mean values 	 the
standard error of the means are reported.
RESULTS AND DISCUSSION
There are few reports concerning the molecular basis for
Bartonella-induced neovascularization in humans. A number of
early reports designed to explain these in vivo phenomena
focused on identifying bacterial factors that were directly mi-
togenic for vascular endothelial cells (10, 16, 17, 27). However,
none of the studies identified the putative proteins responsible.
More recently, work with B. henselae has shown a direct link-
age between paracrine-derived VEGF or cytokines (e.g., IL-8
and IL-1) and enhanced endothelial cell proliferation (22,
29). This proliferative stimulation is also apparently aug-
mented by inhibition of endothelial cell apoptosis by an unde-
scribed, secreted factor from B. henselae (23). Clearly, a com-
plex, multifaceted strategy designed to increase the numbers of
endothelial cell hosts is evidently employed by Bartonella.
B. bacilliformis lysate contains a dose-dependent mitogen for
HUVECs that does not affect apoptosis. To identify an optimal
concentration range for the B. bacilliformis proliferative factor
and to determine if the growth response is dose dependent,
various concentrations of soluble cell lysate were added to
HUVEC cultures. Adherent, viable HUVEC numbers were
indirectly determined after a 96-h culture period by using an
acid phosphatase assay calibrated for use with HUVECs ac-
cording to a linear standard curve (r2  0.99) over the entire
range of acid phosphatase values reported in this study (Fig.
1A). Data show that the B. bacilliformis lysate is dose depen-
dent and saturating at 5 to 10 g of lysate protein per ml of
culture medium and significantly enhances cell numbers (20-
fold) relative to those of controls treated with equal volumes of
heated lysate (Fig. 1B). Activity was lost, regardless of dose, if
the lysate was heated (100°C for 7 min) prior to use. These
data are in agreement with those of Garcia et al. (17), who also
found that the proliferative factor was heat sensitive. Similar
dose-response profiles were obtained if HUVEC numbers
were quantified by an ELISA-based BrdU incorporation assay
(Fig. 1C).
Previous work by Garcia et al. (17) determined that the
factor was not cytotoxic for HUVECs, implicating a molecule
other than LPS. To build upon these observations, we tested
the lysate’s sensitivity to trypsin and polymyxin B (LPS inhib-
itor). Our results indicate that the mitogenic activity is signif-
icantly reduced by trypsin in a dose-dependent fashion (e.g., a
25% reduction in activity results when trypsin is used at 1.7
g/ml) but is not affected by treatment with polymyxin B (data
not shown). Like Garcia et al. (17), we did not observe any
overt morphological differences between HUVECs treated
with lysate and controls in this or any other experiment. Taken
together, these four lines of evidence indicated that the mito-
gen was a lysate protein and not bacterial LPS.
Garcia et al. (17) showed a threefold increase in HUVEC
proliferation in response to B. bacilliformis; a value that is
considerably lower than those observed in this study. We as-
cribe this discrepancy to differences in protocol. Specifically,
Garcia et al. (17) quantified HUVECs by using a Coulter
counter, which enumerates both live and dead cells in control
and test wells. As such, their proliferation data are very differ-
ent from those in the acid phosphatase assay, which indirectly
quantifies only viable cells. In addition, their working medium
and lysate purification and lysate application protocols differed
from those in this study.
We observed considerable variation in HUVEC prolifera-
tive responses to the Bartonella lysate or its fractions between
experiments. We believe this variation is caused by passage
number, because increased HUVEC passage consistently re-
sulted in decreased responsiveness. We therefore employed
HUVECs from passages 2 to 6 and conducted internal controls
on all assays to establish a baseline for that particular experi-
ment. Regardless of the variation seen between individual ex-
periments, the data trends in this study were consistent and
reproducible.
The kinetics of the lysate’s proliferative activity was exam-
ined over a 96-h period. Data show that HUVEC mitogenicity
occurs maximally at approximately 72 h in culture, with cell
numbers stable for at least an additional 24 h (Fig. 2). To
ensure that the increased number of HUVECs was a result of
increased proliferation in response to the lysate and not inhi-
bition of apoptosis as previously reported for HUVECs cocul-
tured with B. henselae (23), we examined BrdU incorporation
over a 48-h period. BrdU incorporation was significantly in-
creased (82% greater) in HUVEC cultures treated with lysate
compared to that in control cultures grown in the presence of
heated lysate (Fig. 3). These data suggest that elevated
HUVEC numbers in response to B. bacilliformis lysate are a
result of increased proliferation rates, suggesting that the fac-
tor is a mitogen.
As a corollary to this experiment, we tested the lysate’s
ability to inhibit HUVEC apoptosis triggered by serum starva-
FIG. 2. Numbers of HUVECs as a function of incubation time in
culture medium containing B. bacilliformis lysate (10 g of protein/ml).
Data were obtained at the indicated times with an acid phosphatase
assay and represent the average of three experiments 	 standard error.
Control experiments with cells grown in M199-FCS (20% vol/vol)
medium only or medium supplemented with heated lysate (100°C for
7 min) were also done.
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tion as previously described by Kirby and Nekorchuk (23). For
this experiment, we chose to measure caspase 3 because of its
central role in programmed cell death (21). As expected,
caspase 3 activity was significantly increased (1.5-fold) in re-
sponse to serum starvation. Z-VAD-FMK, a known inhibitor
of apoptosis (2), significantly reduced caspase 3 activity when
provided to apoptotic HUVECs (5% of serum-starved cells).
However, there was no significant difference in caspase 3 ac-
tivity between serum-starved cells and serum-starved cells sup-
plemented with Bartonella lysate, suggesting that the prolifer-
ative factor does not inhibit apoptosis during a 6-h serum
starvation period (Fig. 4).
B. bacilliformis lysate is significantly more potent than B.
henselae as a mitogen for HUVECs. Previous work by Kirby
and Nekorchuk (23) showed that elevated HUVEC numbers
in cocultures containing B. henselae were primarily caused by
inhibition of apoptosis, rather than stimulation of prolifera-
tion. To examine the apparent discrepancy between the results
of that study and this work, we prepared a B. henselae cell
lysate in a manner similar to B. bacilliformis and assayed its
mitogenic activity in a HUVEC culture. In confirmation of
recent studies (23, 29), B. henselae lysates possessed relatively
minor mitogenic activity (2-fold greater than heated lysate
controls) in contrast to the B. bacilliformis lysate (12-fold
greater than heated lysate controls) (Fig. 5). Interestingly, al-
though these two bacteria are closely related, the existing data
suggest that they may employ different strategies for triggering
endothelial cell proliferation.
Mitogenic activity is located in both soluble and insoluble
fractions of the B. bacilliformis cell and in culture superna-
tants. One inconsistent observation from previous studies of
the Bartonella proliferative factor concerned its cellular loca-
tion within the bacterium. Work with B. henselae suggested the
factor was located in the insoluble, cell wall fraction of the
bacterium (10); however, subsequent work showed it was ap-
parently soluble and secreted (27). In contrast, studies with B.
bacilliformis suggested that its factor was located in the soluble
fraction of a cell lysate (17). Therefore, we fractionated the B.
bacilliformis cell into soluble (lysate) and insoluble (pellet)
fractions and also collected supernatants from 16-h bacterial
cultures. Each fraction (10 g/ml) was then tested for its mi-
togenic activity on HUVECs. Data show that the majority of
FIG. 3. Mitogenicity of the B. bacilliformis lysate for HUVECs, as
demonstrated by BrdU incorporation over a 48-h incubation. Data
were obtained with a BrdU proliferation assay kit (Oncogene) exactly
as previously described for B. henselae (23) and represent the average
of six experiments 	 standard error. Bartonella lysate was used at 10 g
of protein/ml of medium. A control experiment with M199-FCS (20%
vol/vol) medium alone was also done.
FIG. 4. B. bacilliformis lysate does not inhibit caspase 3 activity in
serum-starved HUVECs. Caspase 3 activity as a function of HUVEC
treatment is shown. Data were obtained by serum starving HUVECs
for 6 h in M199 medium containing Z-VAD-FMK (50 M), B. bacil-
liformis lysate (10 g/ml), or no supplement. A negative control ex-
periment with cells grown in M199-FCS (10%) was also done exactly as
previously described (23). Caspase 3 activity data were obtained with a
CaspACE assay kit (Promega) and represent the average of four in-
dependent determinations 	 standard error.
FIG. 5. Comparison of B. bacilliformis and B. henselae lysate mito-
genicities for HUVECs. Data were obtained at 96 h with an acid
phosphatase assay and represent the average of three experiments 	
standard error. Bartonella lysates were used at a final concentration of
10 g of protein/ml of medium. Experiments with HUVECs grown in
M199-FCS (20% vol/vol) medium or medium containing heated lysate
(100°C for 7 min) were done as controls. Bh, B. henselae; Bb, B.
bacilliformis.
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mitogenic activity was found in the soluble lysate fraction (ap-
proximately sixfold increase over heated lysate control), al-
though the insoluble pellet fraction also possessed significant
activity (approximately twofold increase over heated pellet
control) (data not shown). Culture supernatants were also
found to be significantly mitogenic for HUVECs, with a 342-
fold increase in cell numbers relative to HUVEC cultures
supplemented with an equal volume of bacterial culture me-
dium, suggesting that the factor was secreted during bacterial
growth (Fig. 6). It is important to note that the apparent
342-fold increase in adherent cell number was determined
relative to controls containing tissue culture medium supple-
mented with sterile bacterial culture medium and is likely a
result of the extensive death observed in the control wells
(verified by microscopy), not exaggerated growth stimulated by
the supernatant. Parallel experiments using equal concentra-
tions of an E. coli (DH5) culture supernatant showed a lower
but significant (89-fold) increase over HUVEC cultures
treated with bacterial culture medium only. The E. coli mito-
gen is heat resistant and thus likely LPS (Fig. 6).
We therefore analyzed Bartonella culture supernatants for
any bacterium-derived proteins in hopes of identifying a po-
tential candidate for the mitogen. Silver-stained SDS-PAGE
gels (data not shown) and immunoblots developed with anti-B.
bacilliformis whole-cell antibody or antibodies specific to par-
ticular Bartonella proteins identified five Bartonella polypep-
tides in the culture supernatant, including the 42-kDa flagellin
protein (32); three BLP proteins with sizes of 32, 34, and 36
kDa (4); and GroEL (61 kDa) (Fig. 7).
The presence of GroEL correlates with mitogenic activity,
and antibodies to GroEL or GroES inhibit mitogenicity of the
lysate. A B. bacilliformis cell lysate preparation was sequen-
tially fractionated by high-resolution column chromatography
employing a variety of resins. Resulting fractions from each
chromatographic separation were individually tested for
HUVEC mitogenicity in vitro. The mitogenic activity in the
eluted fractions from a hydroxyapatite (CHT-II) column frac-
tionation shows a broad, heat-sensitive peak (Fig. 8A), a fea-
ture also seen in anionic and cationic exchange columns (data
not shown). Fractions corresponding to peak mitogenic activ-
ities for HUVECs were pooled and used in subsequent chro-
matographic fractionations. In addition to assaying HUVEC
mitogenicity, the protein profile for each fraction was obtained
by SDS-PAGE, followed by staining the gel with AgCl to max-
imize sensitivity of protein detection. A protein of 61 kDa
was found to be present in the mitogenic fractions and was not
detected or was barely detectable in fractions that did not
exhibit significant mitogenicity. Given the prominence of this
protein band and its molecular mass, we hypothesized that it
was GroEL. This was verified by using immunoblots developed
with commercial anti-E. coli GroEL IgG (Sigma). An immu-
noblot comparing GroEL levels in a poorly mitogenic CHT-II
fraction (fraction 7 of Fig. 8A) with a significantly mitogenic
CHT-II fraction (fraction 12 of Fig. 8A) is shown in Fig. 8B
(lanes 1 and 2, respectively).
After determining that the protein in the mitogenic fractions
was GroEL, we generated monospecific rabbit anti-B. bacilli-
formis GroEL antiserum and assayed for its inhibitory effect on
the lysate’s mitogenicity. Data from this assay showed that the
anti-B. bacilliformis GroEL antiserum significantly reduces the
FIG. 6. Mitogenicity of the B. bacilliformis culture supernatant.
HUVECS grown in M199-FCS (20% vol/vol) medium containing
equal volumes (45 l) of a filter-sterile supernatant from a B. bacilli-
formis or E. coli DH5 culture (OD600  1.0 for both) were assayed for
HUVEC numbers at 96 h by using an acid phophatase assay. HUVECs
grown in M199-FCS (20% vol/vol) medium alone (none), in tissue
culture medium containing 45 l of sterile bacterial culture medium
(Bact medium), or with heated B. bacilliformis (B.b.) or E. coli (E.c.)
bacterial culture supernatants (Sup; 100°C for 7 min) were also con-
ducted. Data represent the average of three experiments 	 standard
error.
FIG. 7. Immunoblot showing B. bacilliformis proteins translocated
to the growth medium over a 16-h incubation. Culture supernatants
were prepared (see Materials and Methods), separated by SDS-PAGE
(12.5% acylamide), and blotted to nitrocellulose, and the immunoblot
was developed with anti-B. bacilliformis whole-cell antibody (32).
Lanes: 1, medium alone; 2, supernatant from the spent growth me-
dium. The positions of the bacterium-specific proteins, GroEL, flagel-
lin, and the BLPs are indicated. The identity of the proteins was
determined by using immunoblots developed with monospecific anti-
bodies (not shown). Molecular mass standards are indicated to the left
in kilodaltons.
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lysate’s mitogenicity by 40% when compared to that in con-
trols treated with an equal volume of preimmune rabbit serum
(Fig. 9). In fact, preimmune serum, containing growth factors
and multiple irrelevant antibody idiotypes, actually enhanced
HUVEC growth. Our inability to completely abrogate mito-
genic activity with anti-GroEL antiserum suggests that other
proliferative factors may be present in the lysate. Substitution
with PBS-dialyzed commercial anti-E. coli GroEL or GroES
IgG (Sigma) also yielded significant reductions (30 and
39%, respectively) in mitogenicity of the B. bacilliformis ly-
sate relative to that of PBS controls (data not shown). That
anti-GroES antibodies also inhibited activity of the lysate is not
surprising, because GroEL would likely be complexed with
GroES in the Bartonella cell lysate. Taken together, these data
implicate GroEL and potentially the GroEL-GroES complex
of this bacterium as a participant in the observed HUVEC
mitogenicity.
Given the inducibility of groEL during cellular stress, we
hypothesized that temperature upshift to a B. bacilliformis cul-
ture would augment the mitogenicity of its respective lysate. To
examine this possibility, Bartonella cultures were grown for 4
days at 30°C and then upshifted to 37°C for a period of 6 h. Cell
lysates were subsequently prepared from these and parallel
cultures maintained at 30°C. A dose-response comparison of
the resulting lysates showed that at 0.1 to 2.0 g of protein/ml,
lysates from the upshifted cultures produced a significant in-
FIG. 8. Differential HUVEC numbers in response to CHT-II fractions of the B. bacilliformis lysate. (A) HUVEC cultures were grown in
M199-FCS (20% vol/vol) medium containing 40 l of each chromatographic fraction (no. 3 to 23) and assayed at 96 h with an acid phosphatase
assay. The data represent the average of three experiments 	 standard error. Control experiments with cells grown in medium alone (C), medium
with lysate (Lys) at 10 g/ml, or heated samples (100°C for 7 min) were also done. FT and PW cultures were treated with flowthrough and prewash
from the column, respectively. (B) Immunoblot showing absence of GroEL in a fraction with insignificant mitogenicity (lane 1, fraction 7) and a
prominent GroEL band in a highly mitogenic CHT-II fraction (lane 2, fraction 12). A correlation between GroEL presence and mitogenicity was
observed in the other fractions as well (not shown).
FIG. 9. Significant inhibition of HUVEC mitogenicity by pretreat-
ment of the lysate with anti-GroEL antiserum. Pretreatment of B.
bacilliformis lysate with rabbit anti-GroEL antiserum for 2 h prior to
adding it to the M199-FCS (20% vol/vol) culture medium (10 g of
lysate protein/ml) resulted in a significant reduction in mitogenic ac-
tivity compared to that of parallel controls treated with equal volumes
of rabbit preimmune serum (Pre). Samples were assayed at 96 h with
an acid phosphatase assay. The data represent the average of six
experiments 	 standard error.
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crease (15 to 224%) in cell numbers relative to 30°C culture-
lysate counterparts (Fig. 10). There was also a 9% increase at
a 10-g/ml dosage, but the difference was not statistically sig-
nificant from the level in the corresponding 30°C control (data
not shown).
GroEL is found in the inner and outer membranes of B.
bacilliformis and is actively secreted. Although our data re-
vealed that the majority of mitogenicity was located in the
soluble fraction of the B. bacilliformis cell, we also found sig-
nificant activity in the insoluble cell pellet (not shown). This
contradiction is reminiscent of earlier reports suggesting that
the B. henselae proliferative factor was found in both soluble
and insoluble fractions of the bacterium (10, 27). We used
immunoblots to determine if GroEL was present in mem-
branes of B. bacilliformis prepared by sucrose gradient density
ultracentrifugations. The results show that GroEL is present in
both inner and outer membranes of the bacterium and is found
in similar quantities by visual inspection (Fig. 11). The com-
piled data show that GroEL is present in a variety of cellular
locations within B. bacilliformis, including its soluble fraction,
insoluble fraction, and culture supernatant.
Our experiments during this study showed that GroEL was
one of five detectable proteins in culture supernatants analyzed
by SDS-PAGE and immunoblotting (Fig. 7); however, the re-
sults did not directly demonstrate whether GroEL is actively
secreted by B. bacilliformis. To examine this possibility, freshly
harvested bacteria from a 25°C culture were pulse-labeled for
30 min at 25 or 37°C in HIAB broth containing 300 Ci of
[35S]Met/Cys per ml. An aliquot of the culture supernatant was
then separated by SDS-PAGE and blotted to nitrocellulose.
The resulting blot was developed by using anti-E. coli GroEL
IgG (Sigma) and subsequently autoradiographed. The result-
ing autoradiograph shows that within the 30-min incubation
time, a 61-kDA polypeptide (identified as GroEL by the im-
munoblotting prior to autoradiography) was the only radiola-
beled protein in the supernatant, although a minor band of
10 kDa was also detectable after temperature upshift to 37°C
(Fig. 12, lane 2). This small protein may be GroES based upon
its conserved molecular mass among bacteria and the fact that
it complexes with GroEL. As expected, the quantity of secreted
GroEL was greater following a temperature upshift relative to
the 25°C sample (Fig. 12). The mechanism for secretion of
GroEL by Bartonella is unknown, and we are currently inves-
tigating the possible involvement of the Bartonella VirB/VirD
type IV secretion system (33). Secretion of GroEL has been
previously reported in Helicobacter pylori, where the protein
can be found extracellularly in culture supernatants (36) and
may serve to protect secreted urease enzyme (13). In addition,
GroEL secretion has been demonstrated in Legionella pneu-
mophila, where the protein is mainly associated with the cell
envelope of the bacterium (18).
Recombinant GroEL and HUVEC proliferation. Although
in vitro GroEL expression, synthesis, and purification of a
recombinant GroEL fusion protein were successful in our
hands as determined by SDS-PAGE (data not shown), signif-
icant mitogenic activity in HUVEC cultures treated with the
fusion protein was not observed, regardless of dosage (4 ng/ml
to 5 g/ml). Possible reasons for these negative results include
inhibition of activity from the six-His tag on the N terminus of
the fusion protein, lack of the GroES subunit, or an improperly
formed GroEL complex due to overexpression in E. coli.
To overcome these problems, a functional B. bacilliformis
groES-groEL operon was cloned into a multicopy, broad-host-
range shuttle vector to form the plasmid pGRO1. Functional
expression of the operon was verified by complementing a
FIG. 10. Significant increase in mitogenic activity of B. bacilliformis
lysate in response to temperature upshift of the source culture. Shown
are HUVEC numbers in response to increasing doses of B. bacillifor-
mis lysates obtained from a 30°C-grown culture and from a culture
shifted to 37°C for 6 h prior to lysate preparation. Acid phosphatase
assays were done after 96 h of HUVEC growth in M199-FCS (20%
vol/vol) supplemented with lysates from cultures grown under the two
temperature regimens. Data represent the average of three experi-
ments 	 standard error.
FIG. 11. GroEL is present in both inner and outer membranes of
B. bacilliformis. Inner and outer membranes (IM and OM, respec-
tively) of B. bacilliformis were prepared as previously described (8, 9),
separated by SDS-PAGE (12.5% acrylamide), and then blotted to
nitrocellulose. The resulting immunoblot was developed with an anti-
GroEL antiserum. The positions of GroEL are indicated for outer
membranes in lane 1 and inner membranes in lane 2. Molecular mass
standards are given to the left in kilodaltons.
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temperature-sensitive groEL mutant strain of E. coli
(NRK117) (25) with pGROESL-TOPO according to the gen-
eral methods of Radulovic et al. (28; data not shown). A
Bartonella strain transformed with pGRO1 was generated and
designated LSS100. A control strain containing the cloning
vector was also produced and designated LSS001. The relative
level of GroEL in lysates prepared from these strains was
quantified by immunoblot densitometry (not shown) and indi-
cated that levels of GroEL were 70 and 43% greater in LSS100
than in the control strain at treatment temperatures of 30 and
37°C, respectively (Fig. 13). HUVEC mitogenicity assays with
these lysates showed a direct correlation between GroEL levels
and HUVEC mitogenicity (r2  0.85) (Fig. 13). HUVEC num-
bers following treatment with the LSS100 lysate (1.0 g/ml)
were significantly greater than those treated with control
LSS001 lysates: at 30°C, an approximately 4.5-fold increase in
HUVEC number was obtained, and at 37°C, an 2.3-fold
increase was observed (Fig. 13). Similar profiles were also
obtained with lysate supplements of 0.5, 1.5, and 2.0 g/ml,
whereas saturation occurred at concentrations greater than 5
g/ml (data not shown). Lack of a significant difference be-
tween LSS100 lysates from the two temperature treatments
suggests that GroEL saturation occurred.
Although GroEL has been shown to activate endothelial
cells by inducing a variety of cytokines (e.g., granulocyte-mac-
rophage colony-stimulating factor, IL-6, and IL-1) and adhe-
sion molecules (ICAM-1, VCAM-1, and E-selectin) (15, 34),
this report is the first, to our knowledge, to implicate bacterial
GroEL in the proliferation of human vascular endothelial cells.
Interestingly, GroEL mitogenicity for other cell types has been
reported from various pathogenic bacteria. For example,
GroEL from Chlamydia pneumoniae is mitogenic for human
vascular smooth muscle cells in culture (31). GroEL from
Actinobacillus actinomycetemcomitans is mitogenic for epithe-
lial cells at low dose and is cytotoxic at higher concentrations
(20, 40). GroEL from A. actinomycetemcomitans apparently
triggers epithelial cell growth via the ERK1/2 and mitogen-
activated protein kinase signaling pathways (40).
The mechanism whereby B. bacilliformis GroEL serves as a
proliferative factor is unknown, and its role may be indirect.
For example, GroEL from Mycobacterium tuberculosis is a po-
tent stimulator of cytokine synthesis (26). In L. pneumophila,
GroEL can induce IL-1 in macrophages during infection (30)
and correlates with virulence (14). B. bacilliformis GroEL
could possibly stimulate synthesis of angiogenic cytokines by
HUVECs (e.g., IL-6, IL-8, or IL-1), which could act in an
autocrine fashion to stimulate endothelial cell proliferation in
vitro. Given its chaperonin function, GroEL could conceivably
protect or even help fold a mitogenic protein, thereby contrib-
uting to its activity.
Although we did not observe inhibition of HUVEC apoptosis
in cultures treated with B. bacilliformis lysate, inhibition of cell
death via an alternative pathway that does not involve caspase 3
is possible. Previous work has shown that bacterial GroEL or
GroEL fragments can inhibit apoptosis in a variety of mammalian
cells (7, 19). In addition, GroEL is suspected of playing a role in
conferring apoptosis resistance to HeLa 229 cells that are persis-
tently infected with Chlamydia trachomatis (12).
FIG. 12. GroEL is secreted by B. bacilliformis. B. bacilliformis was
harvested and radiolabeled for 30 min at 25 or 37°C in HIAB containing
300 Ci of 35S-Express per ml (NEN-Dupont). Culture supernatants were
subsequently isolated, separated by SDS-PAGE, and blotted to nitrocel-
lulose, and the immunoblot was developed with anti-GroEL antibody.
The blot was then autoradiographed. The resulting autoradiograph is
shown and reveals a single radiolabeled 61-kDa protein identified as
GroEL (arrow) in the 25°C sample (lane 1) and GroEL plus an 10-kDa
radiolabeled protein in the 37°C sample (lane 2, parentheses). Molecular
mass values are given to the left in kilodaltons.
FIG. 13. HUVEC numbers correlate with GroEL levels in the Bar-
tonella lysate treatment. HUVEC numbers in response to treatment
with B. bacilliformis lysates from strains LSS100 (containing pGRO1, a
multicopy plasmid with the groES-groEL operon) and LSS001 (con-
taining the pBBR1-MCS2 vector) cultivated at 30°C or shifted to 37°C
for 6 h prior to lysate preparation. Acid phosphatase assays were done
after 96 h of HUVEC growth in M199-FCS (20% vol/vol) supple-
mented with lysates (1.0 g/ml) from cultures subjected to the two
temperature regimens. GroEL levels in the lysates, relative to those in
the 30°C vector control, were determined by immunoblot densitometry
and are indicated below the corresponding bars of the graph. Data
represent the average of three experiments 	 standard error.
VOL. 71, 2003 BARTONELLA GroEL AND VASCULAR ENDOTHELIAL CELLS 6941
In conclusion, the most important findings from this study
are (i) the B. bacilliformis proliferative factor is a dose-depen-
dent, proteinaceous mitogen for HUVECS that does not in-
hibit apoptosis by the capase 3 pathway within a 6-h serum
starvation period; (ii) the mitogen is found in bacterial culture
supernatants, the soluble cell fraction, and to a lesser degree in
insoluble cell fractions of the bacterium; (iii) soluble cell frac-
tions from B. henselae possess significantly less mitogenicity for
HUVECs than those from B. bacilliformis; (iv) B. bacilliformis
GroEL is a participant in the observed HUVEC mitogenicity;
and (v) GroEL is located in the soluble and membrane frac-
tions of the cell and is actively secreted by B. bacilliformis.
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